<産業資料/調査レポートの題名> 2022年7月19日

チロシンキナーゼ阻害剤の世界市場2019-2023


◆英文タイトル:Global Tyrosine Kinase Inhibitors Market 2019-2023

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• The threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• RTKIs – Market size and forecast 2018-2023
• nRTKIs – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Johnson & Johnson
• Novartis
• Pfizer
PART 13: APPENDIX
• Research methodology
• List of abbreviations

Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: RTKIs – Market size and forecast 2018-2023 ($ billions)
Exhibit 21: RTKIs – Year-over-year growth 2019-2023 (%)
Exhibit 22: nRTKIs – Market size and forecast 2018-2023 ($ billions)
Exhibit 23: nRTKIs – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ billions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ billions)
Exhibit 32: Example of patient-assistance program for cancer treatment
Exhibit 33: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: APAC – Market size and forecast 2018-2023 ($ billions)
Exhibit 36: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Decision framework
Exhibit 41: Reported top 5 new cases of cancer types in US in 2015
Exhibit 01: Treatment costs of TKIs
Exhibit 02: Side effects of TKIs
Exhibit 03: Impact of drivers and challenges
Exhibit 07: Vendor landscape
Exhibit 08: Landscape disruption
Exhibit 09: Vendors covered
Exhibit 10: Vendor classification
Exhibit 11: Market positioning of vendors
Exhibit 12: Bristol-Myers Squibb – Vendor overview
Exhibit 13: Bristol-Myers Squibb – Business segments
Exhibit 14: Bristol-Myers Squibb – Organizational developments
Exhibit 15: Bristol-Myers Squibb – Geographic focus
Exhibit 16: Bristol-Myers Squibb – Key offerings
Exhibit 17: Bristol-Myers Squibb – Key customers
Exhibit 18: F. Hoffmann-La Roche – Vendor overview
Exhibit 19: F. Hoffmann-La Roche – Business segments
Exhibit 20: F. Hoffmann-La Roche – Organizational developments
Exhibit 21: F. Hoffmann-La Roche – Geographic focus
Exhibit 22: F. Hoffmann-La Roche – Segment focus
Exhibit 23: F. Hoffmann-La Roche – Key offerings
Exhibit 24: F. Hoffmann-La Roche – Key customers
Exhibit 25: Johnson & Johnson – Vendor overview
Exhibit 26: Johnson & Johnson – Business segments
Exhibit 27: Johnson & Johnson – Organizational developments
Exhibit 28: Johnson & Johnson – Geographic focus
Exhibit 29: Johnson & Johnson – Segment focus
Exhibit 30: Johnson & Johnson – Key offerings
Exhibit 31: Johnson & Johnson – Key customers
Exhibit 32: Novartis – Vendor overview
Exhibit 33: Novartis – Business segments
Exhibit 34: Novartis – Organizational developments
Exhibit 35: Novartis – Geographic focus
Exhibit 36: Novartis – Segment focus
Exhibit 37: Novartis – Key offerings
Exhibit 38: Novartis – Key customers
Exhibit 39: Pfizer – Vendor overview
Exhibit 40: Pfizer – Business segments
Exhibit 41: Pfizer – Organizational developments
Exhibit 42: Pfizer – Geographic focus
Exhibit 43: Pfizer – Segment focus
Exhibit 44: Pfizer – Key offerings
Exhibit 45: Pfizer – Key customers
Exhibit 46: Validation techniques employed for market sizing
Exhibit 47: List of abbreviations


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark